We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Nephrotoxicity of Combined Cephalothin-Gentamicin Regimen

Fernando Cabanillas, MD; Rafael C. Burgos, MD; Roberto C. Rodriguez, MD; César Baldizón, MD
Arch Intern Med. 1975;135(6):850-852. doi:10.1001/archinte.1975.00330060094013.
Text Size: A A A
Published online


Gentamicin sulfate (Garamycin) is a broad spectrum antimicrobial agent member of the aminoglycoside group of antibiotics. This group, which also includes neomycin sulfate, kanamycin sulfate, and streptomycin sulfate,1 is known to be nephrotoxic. Gentamicin-induced renal damage, however, has been recognized in only 2% of the subjects taking the medication, and this is usually manifested by a mild transient rise in blood urea nitrogen (BUN) level.1,2 Recently, the first instance of severe acute renal failure in a patient receiving this drug only was reported by Kahn and Stein,3 although the structural lesion was not confirmed by biopsy.

Cephalothin sodium (Keflin)-induced renal failure is also rare, and few cases have been reported in the literature.4,5 Five times the usual therapeutic dosage is needed for the experimental production of mild histological changes in the renal tubules.4

We report the cases of two patients with histopathologically demonstrable acute tubular


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.